Needham analyst Michael Matson (NYSE:MATX) maintained a Buy rating on Conmed (NYSE:CNMD) Corp on Thursday, setting a price target of $158, which is approximately 13.08% above the present share price of $139.73.
Matson expects Conmed Corp to post earnings per share (EPS) of $0.46 for the fourth quarter of 2021.
The current consensus among 2 TipRanks analysts is for a Moderate Buy rating of shares in Conmed, with an average price target of $159.
The analysts price targets range from a high of $160 to a low of $158.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $255.16 million and a net profit of $25.71 million. The company's market cap is $4.07 billion.
According to TipRanks.com, Needham analyst Michael Matson is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 15.8% and a 62.50% success rate.
CONMED Corp . operates as a medical technology company, which engages in the development, manufacture and sale of surgical devices and related equipment. It operates through the following geographical segments: United States; Americas excluding the United States; Europe, Middle East, and Africa; and Asia Pacific. Its product lines also include orthopedic surgey and general surgery. The company was founded by Eugene R. Corasanti in 1970 and is headquartered in Utica, NY.